



Illumina CEO Jacob Thaysen speaks at the 2025 J.P. Morgan Health Care Conference. Photo by Illumina

Shaping the future of genomics

From Jacob Thaysen, PhD, chief executive officer

2025, WE'RE READY FOR YOU. Last week, Illumina shared bold moves we're making to advance our strategy in unlocking deeper biology and transforming data into insights. We're leading the genomics revolution, and now, we're also driving discovery at the next frontiers of our industry.

Our groundbreaking work with NVIDIA¹ will make clinical research and drug discovery faster, cheaper, and more accessible—all wins for our customers. The combination of Illumina platforms and AI technologies like NVIDIA's will expand the reach of informatics solutions and be central to transforming our understanding of biology and discovery going forward, creating quantum leaps in the fight against disease.

Our newest collaboration with UK Biobank,² our longstanding partner, builds on our efforts to deepen insights through more comprehensive views of data using our upcoming Illumina Protein Prep solution. These and other pilot and early access opportunities we create across our innovation roadmap help us to keep evolving, and keep pushing our innovation to best meet customer needs.

And our participation in the Truveta Genome Project

with Truveta, Regeneron, Microsoft, and 30 health systems across the United States will help us bring together genetic data from 10 million samples with anonymized medical records to create more integrated biological understanding that can lead to more personalized treatments and better outcomes.

Seeing a trend here? Data is the future, and we're on the front lines—using the skills we've honed over 26 years building an industry and pushing it forward to do the same at its next frontier.

We are making the most complex parts of biology simpler, more affordable, more accessible. And we have the scale, innovation, and experience to do this better than anyone else. To move industries, to shape them.

And that means something—to each of us.

We see a future where you know you have a disease before you have a single symptom. Where you can fight it with the right weapon, a medicine tailored to your specific biology.

That future of making "sick care" truly health care is possible, and I'm proud to stand alongside my Illumina teammates, and our incredible customers and partners around the world, to build it together. ➤

1. [illumina.com/company/news-center/press-releases/press-release-details.html?newsid=845f124d-a4f0-4a9a-82b0-b55415993eee](https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=845f124d-a4f0-4a9a-82b0-b55415993eee)

2. [illumina.com/company/news-center/press-releases/press-release-details.html?newsid=e246b707-1b47-4d28-8ea7-51d380977d3b](https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=e246b707-1b47-4d28-8ea7-51d380977d3b)

For Research Use Only. Not for use in diagnostic procedures.

© 2025 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.